PharmaTelevision - AusBiotech: Anna Lavelle explains how investors can leverage their investment dollar by bringing clinical trials to Australia

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AusBiotech: Anna Lavelle explains how investors can leverage their investment dollar by bringing clinical trials to Australia

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Anna Lavelle, CEO of AusBiotech.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

AusBiotech's view: Growth of Biotechnology industry in Australia over the past year

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech's convention in Adelaide. On this show I have Anna Lavelle, who is CEO of AusBiotech, welcome.

Anna Lavelle:

Hi Fintan, great to see you again always enjoy talking to you.

Fintan Walton:

Good, well thank you very much indeed Anna, because we want to talk about last year we had an interview and that year is passed and so what's happened here in Australia from AusBiotech's point of view?

Anna Lavelle:

It's been pretty action packed in fact I would suggest the best you've had in Australia for biotechnology, if you look at the mergers and acquisition activities, you look at the biotech grant $231 million from the NIH, you look at the licensing deals that across have got and also the fact that they've paid back a dividend 60 cents per share to their investors which is great $100 million dividend so that's terrific for a company with 24 people and you look at the amount of money that's being raised also with capital raising things are looking really optimistic very, very healthy here in Australia, now to be fair of course that's for the listed companies and still the private companies are finding it difficult to raise capital, but the companies that have been in existence for 6 to 10-years are doing very, very well.

Fintan Walton:

So is the maturing in the industry going on?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Anna Lavelle

CEO

At the time of recording this PTV interview Anna Lavelle serves as Chief Executive Officer of AusBiotech. Dr Anna Lavelle was appointed inaugural Chief Executive Officer and Executive Director of AusBiotech Ltd in June 2005. AusBiotech is the peak industry body for biotechnology with over 3,000 members. AusBiotech is part of the Pharmaceutical Industry Council and Chairs the Asia/Pacific biotechnology network. Dr Lavelle also Chairs or is a member of, various Federal and State government committees associated with biotechnology. Previously Dr Lavelle was a Senior Executive with the Australian Red Cross Blood Service (ARCBS), commencing in 1998 as Director responsible for Strategic Planning and Business Development. Prior to joining ARCBS, Dr Lavelle held positions of Chief Executive Officer of a public health organization, Industry Lobbyist for a member organization and commenced employment as an academic at Monash University, Melbourne. Dr Lavelle holds a Doctor of Philosophy in Genetics from the University of Melbourne and is a graduate of the Australian Institute of Company Directors.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

AusBiotech

AusBiotech is Australia's biotechnology industry organization, which represents over 3,000 members, covering the human health, agricultural, medical device, bioinformatics, environmental and industrial sectors in biotechnology. AusBiotech is dedicated to the development, growth and prosperity of the Australian biotechnology industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world. AusBiotech has representation in each Australian state providing a national network to support members and promote the commercialization of Australian bioscience in the national and international marketplaces. The structure is a not-for-profit limited guarantee company managed by a Board elected by members in line with its constitution. AusBiotech membership base includes biotechnology companies, ranging from start-ups to mature multinationals, research institutes and universities, specialist service professionals, corporate, institutional, individual and student members from Australia and overseas. In assessing the current needs and issues faced by Australia's core biotechnology companies, AusBiotech's Strategic Business Plan addresses the requirements to build a favorable environment to enable companies to grow, help them globalize and position Australia as a significant biotechnology industry for increasing international investment and interest.